ClinicalTrials.gg
CompletedNCT02695004Updated Apr 6, 2020

Safety, Tolerability and Pharmacokinetics of DKF-310 ( (Donepezil).

A Phase 1 interventional study of DKF-310 and Placebo in Alzheimer's Disease, sponsored by Dongkook Pharmaceutical Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-04-06.

Sponsored by Dongkook Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 60 studies testing donepezil in Alzheimer Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Donepezil · Alzheimer Disease.

Enrollment
37th of 58
44 · median 79
Started
2016
with 3 others
Phase 1
20 of 60
1 open now
Registered
45th of 60
by date

Among the 60 studies testing donepezil in Alzheimer Disease, this one is the 37th largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2016, is one of 20 in phase 1, and was the 45th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

2 of the 60 studies testing donepezil in Alzheimer Disease are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About donepezil

Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 19 Years to 50 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing donepezil in Alzheimer Disease, or all of them as a file.
02

Study summary

This is a study to evaluate safety, tolerability and PK of DKF-310 IM injection in healthy male volunteers.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men aged 19 to 50 years
  • Body weight 55 to 90 kg and 18.0 to 27.0
  • Voluntarily signed the form
  • Eligible according to the screening test results
  • Available to follow up after drop-out

Exclusion criteria

Exclusion Criteria:

  • disorders or a medical history of hepatic, renal, neurological, respiratory, endocrine, hemato-oncologic, cardiovascular, urological and psychiatric diseases
  • to donepezil, piperidine derivatives and other drugs
  • SBP \<100 mmHg or >150 mmHg, or DBP \<60 mmHg or >100 mmHg
  • Skin and muscle disorders or history of surgery at the injection site
  • or ALT >1.5xULN; /QTcB interval >450 ms
  • History or positive result of drug abuse
  • Prescribed drugs or herbal medicines within 2 weeks, over-the-counter drugs or vitamins within 1 week
  • Participated in other clinical trials within 3 months
  • Donated whole blood within 2 months or apheresis within 1 month, or transfusion within 1 month
  • Alcohol consumption >21 units/week
  • Smoked >10 cigarettes/day within 3 months
  • Caffeine-containing foods
  • Not eligible due to other reasons at the investigator's discretion
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Donepezil 35 mg

    Donepezil 35 mg or placebo

    Drug: DKF-310 · Drug: Placebo

  • Experimental
    Donepezil 70 mg

    Donepezil 70 mg or placebo

    Drug: DKF-310 · Drug: Placebo

  • Experimental
    Donepezil140 mg

    Donepezil 140 mg or placebo

    Drug: DKF-310 · Drug: Placebo

  • Experimental
    Donepezil 210 mg

    Donepezil 210 mg or placebo

    Drug: DKF-310 · Drug: Placebo

  • Experimental
    Donepezil 280 mg

    Donepezil 280 mg or placebo

    Drug: DKF-310 · Drug: Placebo

Interventions

  • Also known as: Donepezil

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. AUC

    0, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 240, 312, 360, 408, 432, 456, 480, 504, 528, 552, 600, 720, 816, 888, 960, 1056h

    Time frame: 1056h

  2. Cmax

    0, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 240, 312, 360, 408, 432, 456, 480, 504, 528, 552, 600, 720, 816, 888, 960, 1056h

    Time frame: 1056h

07

Study locations

1 site
  • Seoul National Univ. Bundang Hospital
    Seongnam, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2016, a primary completion of Mar 2017 and a completion of Mar 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2016
First posted
Mar 1, 2016
Start
Feb 2016
Primary completionActual
Mar 2017
CompletionActual
Mar 2017
Last update
Apr 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02695004
Lead sponsor
Dongkook Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Mar 1, 2016
Start date
Feb 2016
Primary completion
Mar 2017
Completion
Mar 2017
Last update
Apr 6, 2020

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion